Ingevity Lifts 2026 EBITDA Guidance to $380M–$400M on Strong Q2, Absorbs $32M APT Impairment
NGVT sits 77% above its 52-week low of $39.735.
Summary
Ingevity posted Q2 2026 net income of $35.3 million and raised its full-year adjusted EBITDA outlook to $380–$400 million, even as it recorded a $32.1 million impairment on its Advanced Polymer Technologies segment and disclosed a CEO stock sale plan.
Key Events · Earnings and Guidance · NGVT
-
Raised Full-Year EBITDA Guidance
Driven by strong first-half execution across all segments, management lifted 2026 adjusted EBITDA guidance to $380–$400 million, up from prior expectations.
-
Q2 2026 Financial Results
Net sales came in at $314.1 million, down 5% year-over-year due to divestitures, while net income reached $35.3 million, or $1.00 diluted EPS, with both Performance Materials and Advanced Polymer Technologies showing growth.
-
$32.1M Non-Cash Impairment on APT
A long-lived asset impairment charge of $32.1 million was recorded for Advanced Polymer Technologies, as the ongoing sale process pointed to a lower recoverable value.
-
CEO Adopts 10b5-1 Trading Plan
On May 13, 2026, CEO David H. Li adopted a Rule 10b5-1 plan that allows for the sale of up to 20,092 shares over the next year.
Analysis · NGVT · Industrial Applications And Services
A solid second quarter pushed net income to $35.3 million and gave management the confidence to raise full-year adjusted EBITDA guidance to $380–$400 million, underscoring the benefits of a streamlined portfolio after recent divestitures. The quarter did carry a blemish: a $32.1 million non-cash impairment on Advanced Polymer Technologies, reflecting a lower valuation as the sale process advances. Separately, the company disclosed a new CEO 10b5-1 trading plan and continued its aggressive buyback program, having repurchased $87.4 million in stock year-to-date. While the guidance raise grabs the headline, the impairment and insider selling plan add layers of complexity.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 36.5% of the 1062 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.61%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NGVT was trading at $70.19 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $39.74 to $79.29. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.